Scientific articles authored by Novo Nordisk
The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.
Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs
Author(s): Raun K ; von Voss P ; Knudsen LB
Raun K, Dept Pharmacol Res 3, Novo Nordisk AS,Novo Nordisk Pk, DK-2760 Malov, Denmark, firstname.lastname@example.org
Obesity 2007, Vol. 15, pg. 1710-1716
Objectives: To evaluate the efficacy of liraglutide, a new, stable, once-daily human analog of glucagon-like peptide-1, in a new animal model of obesity. Research Methods and Procedures: Liraglutide was administered subcutaneously once daily (7 mu g/kg for 7 weeks) to six female obese Gottingen minipigs. Food intake and feeding patterns were monitored using a novel automated feeding system that allowed continuous recording of food intake. Results: Food intake was strongly suppressed. A steadystate level of reduced food intake was achieved within 3 weeks and was maintained for the remaining 4 weeks of the treatment period. During the 4-week steady-state period with liraglutide treatment, daily food intake was 7.3 +/- 0.3 megajoule (MJ) compared with 18.4 +/- 0.6 MJ in the pre-treatment period and 19.2 +/- 0.5 MJ in the post-treatment period (p<0.001). The food intake in the treatment period was equivalent to the amount of food that would have been offered to normal-weight pigs for maintenance. Body weight decreased 4.3 +/- 1.2 kg (4% to 5%) during the 7 weeks of treatment and increased 7.0 +/- 1.0 kg during the 7 weeks of post-treatment (p<0.01). Appetite suppression was quickly reversed within 4 days after termination of liraglutide administration. Discussion: Overall, liraglutide was well tolerated and had a profound and persistent anorectic effect that resulted in weight loss. These results, in conjunction with the previously established glucose-lowering efficacy of liraglutide, suggest that the anorectic actions of liraglutide will be very important in clinical trials of both obese patients with type 2 diabetes and obese non-diabetic patients.Back